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Introduction
Coagulation factor XIII strongly affects fibrin clot structure and function, and therefore plays a role in the pathophysiology of arterial and venous thromboembolic diseases [1] . FXIII is converted by thrombin into activated FXIII (FXIIIa), which is a transglutaminase that forms e-(c-glutamyl)lysyl cross-links between two polypeptide chains [2] . The enzyme stabilizes fibrin by the formation of primarily c-chain dimers and a-chain polymers. Crosslinking makes fibrin clots insoluble in weak acid or urea [3] , and modifies their mechanical properties by increasing the rigidity and elasticity [4, 5] . This does not originate from alterations in network morphology, but most likely from stiffening of the individual fibers [6] . FXIII-mediated cross-linking probably tightens the coupling between the protofibrils within a fibrin fiber [7] , which is associated with slightly thinner fibers and a higher fiber density in a clot [8] .
Cross-linking might also affect the sensitivity of fibrin clots to fibrinolysis, a process that prevents blood clots from growing and occluding vessels by using the plasminogen-plasmin system [9] . However, this is a topic for which there has been a longlasting debate about both the magnitude of the effect of FXIIIa and the mechanisms involved. When we take a look at the literature, it is useful to distinguish studies that used purified fibrin clots and studies that used plasma or whole blood clots. In purified systems, some authors found no effect of fibrin cross-linking on clot lysis [5, 10] , whereas other authors reported that the molecular cross-links producing a-chain polymers, in particular the very high molecular weight a-chain polymers obtained with elevated FXIIIa concentrations (possible provided by platelets), are associated with the inhibition of fibrinolysis [11] . However, others claimed that resistance to fibrinolysis was not induced by a-chain polymer formation or c-chain dimer formation, but by c-chain multimer formation, which only occurs over a period of hours to days [12] . In studies showing the inhibition of fibrinolysis by cross-linking, the effect is often small [8] .
When plasma or whole blood is used, FXIIIa produces not only intramolecular cross-links within fibrin, but also intermolecular cross-links between fibrin and a 2 -antiplasmin (a 2 AP) [13] . This results in a significant inhibition of physiologically occurring fibrinolysis [14] . The relative contributions of fibrin-fibrin cross-links and fibrin-a 2 AP cross-links to the inhibition of lysis of plasma or whole blood clots by FXIIIa are not yet clear. Jansen et al. [15] reported that fibrin-fibrin cross-linking does not contribute significantly to the resistance of blood clots to fibrinolysis, but that cross-linking of a 2 AP to fibrin is essential. This was recently confirmed by Fraser et al. [16] , who showed that the antifibrinolytic function of FXIII in plasma clots is exclusively expressed through a 2 AP cross-linking to fibrin. In contrast, Reed et al. [17] reported that both fibrin-fibrin and a 2 AP-fibrin crosslinking cause the resistance of experimental pulmonary emboli to fibrinolysis.
Another source of the varying results between different studies is the design of the clot lysis experiments [18] . However, it is still unclear why and how the expression of the inhibition of clot lysis by FXIIIa varies so strongly in different models and assays. Mutch et al. [19] showed that model thrombi formed under flow in a Chandler loop clearly reveal the effect of FXIII on fibrinolysis, but the essential feature of this model for the effect is still unknown. The present study deals with the mechanisms of the inhibition of clot lysis by FXIII, and shows that mechanical clot compaction, which is a model for physiologic clot retraction, is essential for fully revealing the inhibition of plasma clot lysis. [20] . The molar fluorescein/fibrinogen ratio was 6.6.
Materials and methods

Materials
Pooled normal plasma was prepared from citrated platelet-poor plasma from 10 apparently healthy donors, and was always used when plasma or normal plasma is specified in this article. Frozen a 2 AP-deficient plasma was obtained from Affinity Biologicals (Ancaster, Ontario, Canada). Platelet-rich plasma was prepared by centrifugation (265 9 g for 10 min) of citrated blood from three apparently healthy donors, and each plasma was used within 1.5 h after preparation. The platelet count ranged from 346 9 10 9 L À1 to 399 9 10 9 L À1 .
Turbidity assay of plasma clot lysis
The turbidity assay was performed essentially as described previously [21] . However, clotting was induced by thrombin rather than by tissue factor and phospholipid vesicles. In short, plasma was diluted 1. ) and FXIIIa inhibitor (0 mM or 1 mM) in assay buffer. The concentrations refer to the final concentrations in the 100-lL reaction volume. After mixing, each well was covered with 50 lL of paraffin oil, and the microtiter plate was placed into the preheated chamber of a microplate reader (Victor 3 ; PerkinElmer, Waltham, MA, USA), and the turbidity was measured as OD at 405 nm every minute for 120 min at 37°C. The clot lysis time (CLT) was calculated as the time from the midpoint of minimum turbidity to maximum turbidity, which represents clot formation, to the midpoint of maximum turbidity to minimum turbidity, which represents clot lysis. When the clot formation was too rapid, the clotting time was roughly estimated. The assays were performed in triplicate.
Plasma clot lysis assay with and without clot compaction
Aliquots of 80 lL of plasma supplemented with FITClabeled fibrinogen (100 lg mL À1 ) were mixed in Eppendorf tubes with 20 lL of a reaction mixture, consisting of tissue factor (Innovin, diluted 1000-fold), CaCl 2 (20 mM), t-PA (0-100 ng mL
À1
) and FXIIIa inhibitor (0 mM or 1 mM) in turbidity assay buffer. The concentrations refer to the final concentrations in the 100-lL reaction volume. After incubation for 0.5 h at 37°C, the clots were disconnected from the tube wall, and compacted by centrifugation for 1 min at 21 100 9 g. The incubation was then continued for 2.5 h at 37°C with shaking. In the plasma clot lysis assay without clot compaction, the clots were not centrifuged after 0.5 h, but incubated for 3 h at 37°C. After the incubation, all clots were centrifuged for 1 min at 21 100 9 g. Aliquots of 20 lL of the supernatants were mixed with 80 lL of Tris-buffered saline containing 0.01% Tween-20 (in triplicate), and the released fluorescence of FITClabeled fibrin degradation products was determined in the microplate reader with 485 nm and 535 nm as the excitation and the emission wavelengths, respectively, to calculate the extent of lysis. The signal of fully lysed clots was set at 100% lysis. This signal was 13% higher than the signal of the corresponding amount of FITC-labeled fibrinogen, indicating that internal quenching of the fluorescence in FITC-labeled fibrinogen was decreased in FITC-labeled fibrin degradation products.
The assays were additionally performed with a 2 AP-deficient plasma instead of normal plasma. In these experiments, the t-PA concentration range was 0-25 ng mL À1 (final concentrations in the 100-lL reaction volume). In control experiments, a 2 AP-deficient plasma was reconstituted with 45 lg mL À1 purified a 2 AP.
Plasma clot lysis assay with and without platelet-mediated clot retraction
Eppendorf tubes were treated with 1% Tween-20 in water for 5 min to prevent fibrin sticking to the wall. Aliquots of 80 lL of platelet-rich plasma supplemented with FITC-labeled fibrinogen (100 lg mL À1 ) were mixed in these tubes with 20 lL of a reaction mixture, consisting of tissue factor (Innovin, diluted 1000-fold), CaCl 2 (20 mM), t-PA (0-100 ng mL À1 ), cytochalasin D (0 lg mL À1 or 10 lg mL À1 ) and FXIIIa inhibitor (0 mM or 1 mM) in turbidity assay buffer. The concentrations refer to the final concentrations in the 100-lL reaction volume. After incubation for 0.5 h at 37°C, the incubation of the retracted clots (those without cytochalasin D) was continued for 2.5 h at 37°C with shaking. The incubation of the non-retracted clots (those with cytochalasin D) was continued for 2.5 h at 37°C without shaking. The extent of lysis was determined as described above for the compacted and non-compacted clots.
Cross-linking of a 2 AP to fibrin
Clots were prepared essentially as in the plasma clot lysis assay with clot compaction, but with a two-fold increase in size. In more detail, aliquots of 160 lL of plasma were mixed in Eppendorf tubes with 40 lL of a reaction mixture, consisting of tissue factor (Innovin, diluted 1000-fold), CaCl 2 (20 mM) and FXIIIa inhibitor (0 mM or 1 mM) in turbidity assay buffer. The concentrations refer to the final concentrations in the 200-lL reaction volume. Controls did not contain tissue factor and CaCl 2. After incubation for 0.5 h at 37°C, the clots were disconnected from the tube wall, and compacted by centrifugation for 1 min at 21 100 9 g. The extents of compaction, as determined by weight analyses, amounted to 91.1% and 94.7%, respectively, for 0 mM and 1 mM FXIIIa inhibitor. The distribution of a 2 AP after compaction was determined by measuring a 2 AP activity in the clot supernatants, and by performing SDS-PAGE and western blotting of the compacted clots. To this end, the clots were washed five times with 500 lL of Tris-buffered saline containing 0.01% Tween-20 and 1 mM FXIIIa inhibitor, and dissolved in 160 lL of SDS sample buffer (Laemli) containing dithiothreitol for 15 min at 95°C. SDS-PAGE was performed on 7.5% Criterion Tris-HCl gels (Biorad Laboratories, Hercules, CA, USA), and blots were stained with goat anti-human a 2 AP IgG-horseradish peroxidase (Affinity Biologicals) and BM blue POD substrate (Sigma-Aldrich).
Miscellaneous a 2 AP activity was determined with a chromogenic substrate method (Berichrom a 2 AP kit; Siemens Healthcare, Erlangen, Germany). Statistical analyses were performed with SPSS for Windows, version 17.0 (SPSS, Chicago, IL, USA), with the independent samples t-test. P-values of < 0.05 were considered to be statistically significant.
Results
Effect of FXIII in a turbidity assay of plasma clot lysis
The effect of FXIII on plasma clot lysis was assessed by using the transglutaminase/FXIIIa inhibitor 1,3-dimethyl-2-[(2-oxo-propyl)thio]imidazolium chloride (FXIIIa inhibitor). Citrated plasma was supplemented with t-PA, and clotted with calcium and three different concentrations of thrombin (0.2, 1.0 and 3.3 NIH U mL À1 ) in the presence or absence of 1 mM FXIIIa inhibitor. Each thrombin concentration yielded a somewhat different but reproducible clot lysis profile (Fig. 1) . FXIIIa inhibitor reduced the CLT from 43.9 AE 0.3 min to 37.8 AE 1.1 min (mean AE standard deviation, n = 3, P = 0.001; 14% reduction) at 0. this assay without compaction, similarly as in the turbidity assay.
With clot compaction, 50% clot lysis was obtained at 80.0 AE 22.6 ng mL À1 t-PA in the absence of FXIIIa inhibitor and at 10.4 AE 1.9 ng mL À1 t-PA, i.e. 7.7-fold less t-PA, in the presence of FXIII inhibitor ( Fig. 2B ; Table 1 ; P = 0.006). These results showed that FXIIIa inhibitor strongly accelerated clot lysis, implying that FXIII effectively inhibited fibrinolysis in this assay with clot compaction, far more than in the assay without clot compaction.
Role of a 2 AP
In order to determine to what extent the cross-linking of a 2 AP to fibrin was responsible for the inhibition of plasma clot lysis by FXIIIa, assays similar to those shown in Fig. 2A 3B ; Table 1 ; P = 0.898). These results showed that FXIIIa inhibitor had no significant effects on clot lysis under these conditions, either with or without clot compaction.
To prove that the absence of an effect of FXIIIa inhibitor was really attributable to the deficiency of a 2 AP and not to other variations in the plasma, a 2 AP-deficient plasma was supplemented with 45 lg mL À1 purified a 2 AP, and plasma clot lysis was measured with clot compaction. In the presence of FXIIIa inhibitor, 50% clot lysis was obtained at a 6.0-fold lower t-PA concentration than in the absence of FXIIIa inhibitor (data not shown), which is close to the factor of 7.7 obtained with normal plasma (Table 1) .
These results indicated that the inhibitory effects of FXIII on fibrinolysis can be fully ascribed to cross-linking of a 2 AP to fibrin, both in the assay with clot compaction and in the assay without clot compaction.
Effect of FXIII on plasma clot lysis with and without platelet-mediated clot retraction
The effect of FXIII on plasma clot lysis was also assessed with platelet-rich plasma samples from three different donors. Clot retraction occurred within 20 min. Control clots that did not retract were prepared in the presence of cytochalasin D. With these non-retracted clots, 50% clot lysis was obtained at 72.0 AE 14.7 ng mL -1 t-PA in the absence of FXIIIa inhibitor and at 55.1 AE 9.6 ng mL Table 1 ; P = 0.004). These results showed that FXIIIa inhibitor strongly accelerated clot lysis, implying that FXIII effectively inhibited fibrinolysis in this assay with clot retraction, far more than in the assay without clot retraction.
Distribution of a 2 AP after clot compaction
To obtain a better understanding of why compacted clots fully revealed the antifibrinolytic and a 2 AP-dependent effect of FXIII, the distribution of a 2 AP after clot compaction was determined. As shown in Fig. 5A , the supernatant of a compacted plasma clot contained 68.8% a 2 AP of the unclotted control plasma, indicating that 31.2% remained in the clot. In contrast, in the presence of FXIIIa inhibitor, the supernatant contained 96.1%, indicating that only 3.9% remained in the clot, and that nearly all a 2 AP was expelled from the clot during compaction. In other words, FXIII ensures that a significant amount of a 2 AP remains in the clot during compaction. This was confirmed in the experiment shown in Fig. 5B . Lanes 1-4 showed that, in the absence of FXIIIa inhibitor, the fibrin c-chain was fully converted into c-dimer, and the fibrin a-chain partially into a-polymers (> 150 kDa). Lanes 6-9 showed no a 2 AP in the clots prepared in the presence of FXIIIa inhibitor, but significant amounts of a 2 AP in complex with a-chain and a-polymers in the clots prepared in the absence of FXIIIa inhibitor. These experiments also showed that the concentration of FXIIIa inhibitor (1 mM) was sufficiently high to block FXIIIa, and that there was hardly any clot binding or incorporation of a 2 AP in the absence of crosslinking.
Discussion
This study further elucidates the mechanisms of the antifibrinolytic effect of FXIII, and clarifies the literature on this topic. Lysis of plasma clots without compaction, as tested in the turbidity assay ( Fig. 1 ) and in the assay with FITC-labeled fibrin ( Fig. 2A) , was slightly but significantly inhibited by FXIIIa. In the latter assay, a 1.6-fold higher t-PA concentration was required for 50% lysis in the presence of (endogenous) FXIIIa than in the absence of FXIIIa ( Table 1) . As the inhibition of clot lysis by FXIIIa was absent in clots from a 2 AP-deficient plasma (Fig. 3A) , the inhibition was caused by cross-linking of a 2 AP to fibrin, and not by molecular cross-links within fibrin. Our results imply that fibrin-bound a 2 AP is a more efficient inhibitor of t-PA-induced fibrinolysis than free a 2 AP in solution. The likely mechanism is that fibrin-bound a 2 AP is localized on the fibrin surface, where t-PA-induced plasminogen activation occurs and plasmin has to perform its function. Our results are largely in agreement with those of Sakata et al. [14] , although this study did not present data for non-compacted clots.
Other studies failed to show reproducible effects of FXIII on lysis of non-compacted plasma clots [19] , probably because the effects are small. a 2 AP circulates in two forms: a native form with a methionine (Met) at the N-terminus, and a 12-residue smaller form with an asparagine (Asn) at the N-terminus [22] [23] [24] . Met-a 2 AP becomes cross-linked to fibrin approximately 13 times more slowly than Asn-a 2 AP, resulting in a strongly (~50%) decreased CLT in a turbidity assay [22] . However, the latter observation seems to be at odds with the small effect of a total blockade of cross-linking with the FXIIIa inhibitor in the turbidity assay of the present study (14-21% decrease), and requires more research.
The most striking result of our study was that lysis of compacted plasma clots was strongly inhibited by FXIIIa. In the presence of (endogenous) FXIIIa, a 7.7-fold higher t-PA concentration was required for 50% lysis than in the absence of FXIIIa (Table 1) . Again, as the inhibition was not found in clots from a 2 AP-deficient plasma (Fig. 3B) , the inhibition was caused by cross-linking of a 2 AP to fibrin, and not by molecular cross-links within fibrin. Lysis of compacted clots was strongly inhibited by FXIII, most likely because FXIIIa prevented a 2 AP from being expelled from the clot during compaction. In the presence of FXIIIa, 31.2% of the a 2 AP remained associated with the clot, whereas in the absence of FXIIIa only a negligible amount, i.e. 3.9%, of a 2 AP remained in the clot (Fig. 5) . The very low clot binding or incorporation of a 2 AP in the absence of cross-linking does not confirm the strong non-covalent interaction of a 2 AP with fibrin as observed with surface plasmon resonance [25] . The present study shows that two mechanisms are involved in the inhibition of lysis of compacted plasma clots by FXIIIa: (i) cross-linked a 2 AP is a more efficient inhibitor of plasmin generated by t-PA on the fibrin surface than free a 2 AP (small effect); and (ii) cross-linking of a 2 AP ensures that a significant proportion of a 2 AP remains associated with the clot during compaction (large effect). These mechanisms are consistent with the observation that a non-cross-linking derivative of a 2 AP produced significantly less inhibition of lysis of compacted plasma clots than native a 2 AP [14] . The critical role of compaction explains a long-standing controversy between Gaffney and Whitaker [26] , who found a strong inhibitory effect of FXIII on lysis of plasma clots harvested by being wound onto a glass rod (i.e. compaction), and Rampling and Flexman [18] , who found no inhibitory effect when testing undisturbed plasma clots (i.e. no compaction). The role of compaction could also explain a more recent observation that model thrombi formed under flow in a Chandler loop reveal the inhibitory effect of FXIII on fibrinolysis [19] . Our results indicate that it is not the flow that represents the essential feature, but the compaction of the clots that coincidentally takes place in a Chandler loop. Flow in general is not necessarily associated with compaction, and should not be considered as being essential for the expression of the antifibrinolytic effect of FXIII.
The Chandler thrombus was presented as a model in which the effects of cross-linking on fibrinolysis can be determined quantitatively [19] . This model does indeed seem to be convenient for resolving many remaining questions concerning the role of cross-linking in fibrinolysis. However, for testing large numbers of samples, e.g. from patient studies, the model would be less convenient. For this purpose, mechanical compaction of clots by a simple centrifugation step, as performed in this study, may be more suitable.
As mentioned above, no inhibition of fibrinolysis by FXIIIa could be demonstrated with clots prepared from a 2 AP-deficient plasma, either with or without clot compaction. This suggests that the inhibition resulting from the formation of fibrin-fibrin cross-links was too small for detection in this system, and agrees with earlier reports that fibrin-fibrin cross-linking does not contribute significantly to the resistance of clots to fibrinolysis [15, 16] . However, we cannot exclude the possibility that stronger cross-linking resulting in very high molecular weight achain polymers [11] and/or c-chain multimers [12] would have resulted in resistance to fibrinolysis independently of a 2 AP. The latter structures could also have been responsible for the observed resistance of experimental pulmonary emboli to fibrinolysis by fibrin-fibrin cross-links [17] .
This study shows that the inhibition of fibrinolysis by FXIIIa is most pronounced in fibrin clots that are compacted, because, in these clots, FXIIIa determines the amount of a 2 AP that remains associated with the clot (Fig. 6) . In vivo clot compaction occurs by plateletmediated clot retraction. The clot lysis results of this study were confirmed with experiments in which compaction was achieved by platelet-mediated clot retraction rather than by centrifugation (Fig. 4) , suggesting that this study has in vivo relevance.
It is anticipated that the timing of a 2 AP cross-linking and clot retraction may be important. In vitro experiments have shown that a 2 AP cross-linking occurs within a few minutes, whereas clot retraction requires dozens of minutes, suggesting that a 2 AP cross-linking is nearly complete before clot retraction starts. However, in vivo data are limited, particularly in pathologic conditions. In theory, both delayed a 2 AP cross-linking and accelerated retraction could result in an a 2 AP-poor clot, possibly leading to faster clot lysis and a bleeding tendency. Not only the timing but also the extent of a 2 AP cross-linking to fibrin could regulate fibrinolysis. In vitro data from previous studies [13, 27] and from the present study (Fig. 5A) show that only a proportion of a 2 AP is cross-linked to the fibrin clot, suggesting that both increased and decreased crosslinking could occur in vivo, potentially leading to a thrombotic tendency and a bleeding tendency, respectively. However, it is still not known how strongly the cross-linking of a 2 AP varies among healthy individuals or patients. Only a few preliminary reports have dealt with this topic [28] [29] [30] [31] , and more clinical research is needed. critically revised the manuscript. J. J. M. C. Malfliet performed the experiments and critically revised the manuscript. F. W. G. Leebeek critically revised the manuscript. S. Uitte de Willige designed the study, interpreted the data, and critically revised the manuscript.
